Lifyorli Kit
NDC Package 76346-425-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Lifyorli (relacorilant) kits is lIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab [see Clinical Studies (14)]. This formulation utilizes a kit delivery system. Marketed by Corcept Therapeutics Incorporated, this product is identified by NDC 76346-425 and is authorized under FDA application NDA220641.

Identification & Billing

NDC Package Code
76346-425-01
Package Description
1 BLISTER PACK in 1 CARTON / 1 KIT in 1 BLISTER PACK (76346-425-11) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-025-01) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-100-01)
Product Code
76346-425
11-Digit Billing Format
76346042501
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Lifyorli
Non-Proprietary Name
Relacorilant
Dosage Form
Kit - A packaged collection of related material.
Administration Route
Oral - Administration to or by way of the mouth.
Usage Information
LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab [see Clinical Studies (14)].

Regulatory & Marketing

Labeler Name
Corcept Therapeutics Incorporated
Product Type
Human Prescription Drug
FDA Application #
NDA220641
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-25-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 76346-425-01 identifies a specific commercial package of 1 blister pack in 1 carton / 1 kit in 1 blister pack (76346-425-11) * 1 capsule in 1 package, combination (76346-025-01) * 1 capsule in 1 package, combination (76346-100-01) of Lifyorli, a human prescription drug labeled by Corcept Therapeutics Incorporated. This kit is formulated for oral use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Corcept Therapeutics Incorporated on March 25, 2026. The current certification is valid through December 31, 2027.

How is this Corcept Therapeutics Incorporated product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 76346042501. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
76346-425-01
11-Digit CMS (5-4-2)
76346-0425-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.